MX375925B - Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. - Google Patents

Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.

Info

Publication number
MX375925B
MX375925B MX2016015248A MX2016015248A MX375925B MX 375925 B MX375925 B MX 375925B MX 2016015248 A MX2016015248 A MX 2016015248A MX 2016015248 A MX2016015248 A MX 2016015248A MX 375925 B MX375925 B MX 375925B
Authority
MX
Mexico
Prior art keywords
sup
treatment
muscular atrophy
spinal muscular
pyrazin
Prior art date
Application number
MX2016015248A
Other languages
English (en)
Other versions
MX2016015248A (es
Inventor
Emmanuel Pinard
Hasane Ratni
Luke Green
Patrick Williamson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016015248A publication Critical patent/MX2016015248A/es
Publication of MX375925B publication Critical patent/MX375925B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención proporciona compuestos de fórmula (I) en donde A, X1, X2, R1, R2, R3, R4 y R5 son como se describe en el presente documento, así como sales farmacéuticamente aceptables de los mismos. Además, la presente invención se refiere a la fabricación de los compuestos de fórmula (I), composiciones farmacéuticas que los comprenden y su uso como medicamentos para el tratamiento de la atrofia muscular espinal.
MX2016015248A 2014-06-25 2015-06-22 Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal. MX375925B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14173935 2014-06-25
PCT/EP2015/063894 WO2015197503A1 (en) 2014-06-25 2015-06-22 Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
MX2016015248A MX2016015248A (es) 2017-02-23
MX375925B true MX375925B (es) 2025-03-07

Family

ID=50980240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015248A MX375925B (es) 2014-06-25 2015-06-22 Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.

Country Status (10)

Country Link
US (1) US9975900B2 (es)
EP (1) EP3160967B1 (es)
JP (1) JP6675334B2 (es)
KR (1) KR102565544B1 (es)
CN (1) CN106459067B (es)
BR (1) BR112016026951B1 (es)
CA (1) CA2952895C (es)
MX (1) MX375925B (es)
RU (1) RU2725979C2 (es)
WO (1) WO2015197503A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2915764A1 (en) 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Screening method
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
ES3072590T3 (en) * 2017-10-03 2026-07-02 Hoffmann La Roche New treatment of sma
KR102740831B1 (ko) * 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
KR102775718B1 (ko) 2017-11-14 2025-03-06 칠드런'즈 메디컬 센터 코포레이션 인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
WO2020004594A1 (ja) 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
JP7576552B2 (ja) * 2019-01-18 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるその使用
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2021007378A1 (en) 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease
AU2021228284A1 (en) * 2020-02-28 2022-09-29 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2021231571A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
WO2023283372A1 (en) * 2021-07-07 2023-01-12 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
CN117957225A (zh) * 2021-07-07 2024-04-30 渤健马萨诸塞州股份有限公司 用于靶向irak4蛋白的降解的化合物
AU2022394333A1 (en) 2021-11-17 2024-06-27 Chdi Foundation, Inc. HTT modulators for treating Huntington’s disease
CN118748995A (zh) * 2021-12-03 2024-10-08 亚根达医疗公司 5-嘧啶甲酰胺衍生物和其使用方法
AR132351A1 (es) 2023-04-13 2025-06-18 Syngenta Crop Protection Ag Derivados de imidazo[1,2-a]pirazina

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085252A1 (en) * 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
CN101790526A (zh) * 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
US9284317B2 (en) * 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
MX352861B (es) * 2011-12-30 2017-12-13 Ptc Therapeutics Inc Compuestos para tratar la atrofia muscular espinal.
AR091022A1 (es) * 2012-05-11 2014-12-30 Abbvie Inc Inhibidores del nampt
US9212209B2 (en) * 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
JP2016500073A (ja) * 2012-11-19 2016-01-07 ノバルティス アーゲー 寄生虫病の処置のための化合物および組成物
CA2913785C (en) * 2013-06-25 2021-08-31 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy

Also Published As

Publication number Publication date
CA2952895A1 (en) 2015-12-30
JP2017520570A (ja) 2017-07-27
BR112016026951A2 (es) 2017-08-15
JP6675334B2 (ja) 2020-04-01
WO2015197503A1 (en) 2015-12-30
RU2725979C2 (ru) 2020-07-08
MX2016015248A (es) 2017-02-23
BR112016026951B1 (pt) 2022-09-20
RU2017102014A (ru) 2018-07-27
EP3160967B1 (en) 2019-05-08
US9975900B2 (en) 2018-05-22
US20170197969A1 (en) 2017-07-13
CN106459067B (zh) 2019-05-31
EP3160967A1 (en) 2017-05-03
KR20170018076A (ko) 2017-02-15
KR102565544B1 (ko) 2023-08-10
RU2017102014A3 (es) 2019-01-22
CA2952895C (en) 2023-09-26
CN106459067A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
MX384868B (es) Composiciones para tratar atrofia muscular espinal.
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
MX2015017345A (es) Compuestos para tratar atrofia muscular espinal.
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
EP4252848A3 (en) Oxysterols and methods of use thereof
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
TW201613864A (en) Novel compounds
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
MY169266A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide

Legal Events

Date Code Title Description
FG Grant or registration